GEF-Inhibitors: New small molecules for the treatment of autoimmune and malignant diseases

Scientists at the University of Bonn have identified new small molecules which can be used for the treatment of diseases characterized by alterations of proteins which are affected by Guanine nucleotide Exchange Factors (GEFs). Proteins targeted by GEFs are involved in integrin signalling, vesicle transport, or MAPK-signalling. These processes play an important role in the modulation of the immune response. Therefore, abnormal activation of the target proteins of GEFs can cause autoimmune and tumor diseases in humans.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Building lighter with concrete

How concrete 3D printing saves material and CO2. “As soon as climate compatibility comes into play we have to look at mineral building materials. And this is where the really…

Optical cavities could provide new technological possibilities

Light and molecules behave in very special ways in optical cavities. Don’t think this is important to you? It may be soon. A research team from the Norwegian University of…

Finding superconductivity in nickelates

Arizona State physicist uses intuition, supercomputers to identify new high-temperature superconductor. The study of superconductivity is littered with disappointments, dead-ends, and serendipitous discoveries, according to Antia Botana, professor of physics at…

Partners & Sponsors